Form D — CASI Pharmaceuticals, Inc.
0001962738-26-000002 · filed 2026-01-28
Offering
- Industry
- Pharmaceuticals
- Exemptions
- 06b
- Total offering
- $5,000,000
- Total sold
- $5,000,000
- Minimum investment
- $0
- Investors
- —
- Sales commission
- —
- Finders' fees
- —
Issuer
- Name
- CASI Pharmaceuticals, Inc.
- CIK
- 1962738
- Entity
- Other
- Jurisdiction
- CAYMAN ISLANDS
- Year incorporated
- 2023
- Address
- 1701-1702, CHINA CENTRAL OFFICE TOWER 1
BEIJING, F4 100025 - Phone
- 86 10 6561 8789
Related persons
-
Wei-Wu He · DirectorBeijing, F4
-
Zhenbo Su · DirectorBeijing, F4
-
Thomas Folinsbee · DirectorBeijing, F4
-
Alexander Y. Wu · DirectorRockville, MD
-
Xuebo Zeng · DirectorBeijing, F4
-
Wei Gao · Executive OfficerBeijing, F4
-
Kun Qian · Executive OfficerBeijing, F4
-
Chunhua Wang · Executive OfficerBeijing, F4
-
Hai Huang · Executive OfficerBeijing, F4
-
Wei (Larry) Zhang · Executive OfficerSouth San Francisco, CA
-
Alexander A. Zukiwski · Executive OfficerSouth San Francisco, CA
-
David Cory · Executive OfficerSouth San Francisco, CA
-
James Huang · DirectorSouth San Francisco, CA
-
Barbara Krebs-Pohl · DirectorSouth San Francisco, CA
View original on SEC EDGAR.